Patents

Alexion issued key patent for eculizumab in Japan

Published in Blood Weekly, March 23rd, 2006

Alexion Pharmaceuticals, Inc., (ALXN) reported that the Japanese Patent Office has issued Patent No. 3734266, entitled "Methods and Compositions for the Treatment of Glomerulonephritis and Other Inflammatory Diseases," which relates to the company's lead product, Soliris brand of eculizumab.

The issued claims encompass the use of Alexion's lead drug candidate, eculizumab, to inhibit complement activation in humans. Complement inhibition is the key mechanism of action for eculizumab in paroxysmal nocturnal hemoglobinuria (PNH), which Alexion is currently developing under the brand name Soliris.

"The issuance of this Japanese patent represents a key...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2006-03-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry